Sarepta Therapeutics Inc SRPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SRPT is a good fit for your portfolio.
News
-
Outperforming ETF manager names a potential '50-bagger' in the stock market
-
Outperforming ETF manager names a potential -2-
-
Outperforming ETF manager names a potential '50-bagger' in the stock market
-
Outperforming ETF manager names a potential -2-
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sarepta Therapeutics to Present at Upcoming Investor Conferences
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
Trading Information
- Previous Close Price
- $117.29
- Day Range
- $115.93–119.08
- 52-Week Range
- $55.25–159.89
- Bid/Ask
- $109.34 / $130.80
- Market Cap
- $11.06 Bil
- Volume/Avg
- 546,229 / 879,032
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.76
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,314
- Website
- https://www.sarepta.com
Comparables
Valuation
|
Metric
|
SRPT
|
MRNA
|
RARE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 38.63 | — |
Price/Book Value | 12.86 | 2.86 | 13.18 |
Price/Sales | 8.76 | 5.87 | 7.47 |
Price/Cash Flow | — | — | — |
Price/Earnings
SRPT
MRNA
RARE
Financial Strength
|
Metric
|
SRPT
|
MRNA
|
RARE
|
|---|---|---|---|
Quick Ratio | 3.23 | 3.21 | 2.32 |
Current Ratio | 3.95 | 3.42 | 2.61 |
Interest Coverage | −26.54 | −113.82 | −8.62 |
Quick Ratio
SRPT
MRNA
RARE
Profitability
|
Metric
|
SRPT
|
MRNA
|
RARE
|
|---|---|---|---|
Return on Assets (Normalized) | −1.58% | −20.12% | −33.88% |
Return on Equity (Normalized) | −7.14% | −26.85% | −233.97% |
Return on Invested Capital (Normalized) | −4.76% | −26.68% | −182.73% |
Return on Assets
SRPT
MRNA
RARE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vptvfhyfns | Fzcm | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ylylfzjp | Lwkrc | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gpqpdsls | Mmfwnxt | $98.9 Bil | |
MRNA
| Moderna Inc | Nbbkfyg | Vnfg | $39.7 Bil | |
ARGX
| argenx SE ADR | Spmrzqt | Wjg | $22.1 Bil | |
BNTX
| BioNTech SE ADR | Hprlsfls | Gwsd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zrfxpcxf | Zhnkgl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fvvyxhsnx | Fmsgqdb | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cbtncvss | Mkklgdl | $12.3 Bil | |
INCY
| Incyte Corp | Qqqylmffr | Lqzgxb | $11.8 Bil |